WHO urges ‘immediate action’ after cough syrup deaths

London Jan 23 (Reuters) – The World Health Organization has called for immediate action to protect children from contaminated medicines in the wake of a spike in child deaths linked to cough medicine last year.

Gambia by 2022; More than 300 children under the age of 5, mainly in Indonesia and Uzbekistan, have died from acute kidney injury linked to contaminated medicines, the WHO said on Monday.

Over-the-counter cough syrups contain high levels of diethylene glycol and ethylene glycol.

“These contaminants, like the toxins and refrigerants used as industrial solvents, can be life-threatening even in small amounts and should never be found in medicines,” the WHO said.

Also Read :  COP27: Summit agrees on climate fund for 'loss and damage' in landmark deal

Philippines Timor Leste The WHO told Reuters on Monday that Senegal and Cambodia could be affected by the sale of the drug. It calls on its 194 member states to take action to prevent further deaths.

“As these are not isolated incidents, WHO is calling on key stakeholders involved in the medical supply chain to coordinate and take immediate action.

Also Read :  Wall St slips in choppy trading on rising recession worries

The WHO has already issued specific product warnings in October and earlier this month for cough medicines made by India’s Maiden Pharmaceuticals and Marion Biotech, which have been linked to deaths in Gambia and Uzbekistan, respectively.

The four Indonesian manufacturers selling locally are PT Yarindo Farmatama; PT Universal Pharmaceutical; A warning was also issued last year for cough medicines made by PT Konimex and PT AFI Pharma.

Related companies have denied that their products are contaminated while investigations are ongoing.

The WHO further called for the above-mentioned flagged products to be removed from circulation, and more broadly for countries to ensure that medicines sold by competent authorities are approved. to examine the producers; It also calls on governments and regulators to increase market surveillance and commit resources to take action where necessary.

Also Read :  Israel hits Gaza as conflict flares after West Bank clashes

to purchase raw materials only from qualified suppliers; Manufacturers are being asked to test their products more thoroughly and keep process records. Importers and distributors should check for signs of falsification and only distribute or sell drugs that are approved for use, WHO said.

Reporting by Jennifer Rigby; Edited by Mark Heinrich and Christina Fincher.

Our Standards: Thomson Reuters Trust Principles.


Leave a Reply

Your email address will not be published.

Related Articles

Back to top button